1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Boryung Corporation

Boryung Corporation

KKRX:003850
8,380.00
KRW
-140.00
(-1.64%)
1,434.49EPS
5.86P/E
710.48BMarket Cap
Feb 08Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5,377.59
5,922.63
6,615.71
47,774.72
1,477.95
8,136.39
8,438.22
7,898
10,040.72
11,544.8
13,043.16
14,898.76
12,119.97
12,614.73
Basic EPS, GAAP
232.12
355.71
334.64
655.55
198.23
358.87
518.62
377.51
689
636
610
1,020
766
1,434.56
Free Cash Flow per Basic Share
253.59
-121.38
-52.87
-2,039.42
-320.42
-321.89
-350.17
-166.64
13.6
-1,444.95
286.4
886.36
1,229.77
-1,937.87
Dividend per Share
16.6
17.49
24.41
181.75
5.66
120.17
40.6
59.09
72.21
100.02
99.94
99.12
100.02
- -
Book Value per Share
2,898.98
3,226.63
3,560.92
3,587.06
4,364.66
4,526.28
5,000.84
6,156.99
7,192.2
7,832.87
8,331.34
9,343.45
10,008.26
10,591.89
Tangible Book Value per Share
2,582.69
2,923.37
3,224.27
3,260.5
4,058.62
4,218.51
4,723.79
5,148.16
5,783.41
5,044.73
5,706.77
7,496.85
8,306.83
5,655.87
Basic Weighted Avg Shares
61
61
61
9
286
57
62
71
62
66
66
68
84
84
Sales/Revenue/Turnover
327,279
359,491
401,350
409,140
422,721
460,402
524,269
561,867
627,279
760,476
859,626
1,017,107
1,017,427
1,060,336
Operating Margin (%)
5.85
6.8
6.86
5.38
0.24
5.42
7.45
7.12
6.61
7.44
7.94
6.93
6.4
6.86
Depreciation Expense
10,553
11,125
12,781
15,320
16,257
16,142
17,428
27,566
32,074
37,644
44,387
42,849
43,522
47,390
Net Income, GAAP
14,127
21,591
20,301
5,614
56,699
20,307
32,222
26,856
43,044
41,894
40,203
69,633
64,303
120,583
Effective Tax Rate (%)
30.46
24.55
27.02
73.84
26.06
23.57
24.13
25.48
39.03
28.76
28.58
- -
7.94
18.36
Profit Margin (%)
4.32
6.01
5.06
1.37
13.41
4.41
6.15
4.78
6.86
5.51
4.68
6.85
6.32
11.37
Working Capital
65,248
79,335
82,635
66,410
112,342
94,809
92,637
192,789
281,361
60,895
176,576
392,234
407,973
240,468
LT Debt
- -
2,482
1,250
- -
27,400
54,291
72,587
170,400
189,231
94,552
152,582
126,338
259,103
249,126
Total Equity
159,980
177,356
195,940
195,349
249,654
256,103
282,954
340,288
474,314
516,417
549,253
784,503
845,503
894,808
Return on Invested Capital (%)
6.78
8.95
8.48
2.28
0.27
5.81
8.07
6.45
4.07
5.57
6.44
- -
5.55
4.86
Return on Capital (%)
7.84
11.06
9.05
2.47
21.31
6.19
8.91
6.42
7.48
6.53
6.36
- -
7.04
10.89
Return on Common Equity (%)
9.24
12.8
10.88
2.87
25.48
8.03
11.95
8.62
10.58
8.47
7.55
10.45
7.89
14.38

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
70,917
55,623
139,735
LT Borrowings
244,668
218,230
235,837
LT Finance Leases
14,435
14,050
13,288
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
84
84
84
Market Capitalization
761,169
760,324
710,481

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
662,938
672,409
577,857
Cash, Cash Equivalents & STI
254,683
263,936
135,029
Accounts Receivable, Net
168,445
154,728
167,438
Inventories
219,444
237,229
256,048
Total Current Liabilities
254,965
257,181
337,389
Payables & Accruals
- -
- -
- -
ST Debt
70,917
55,623
139,735
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.61%
21.05%
7.78%
Free Cash Flow
-1,047.18%
-2,246.98%
70.61%
Net Income, GAAP
93.45%
23.82%
-7.65%
Sales/Revenue/Turnover
9.95%
12.85%
0.03%
Total Cash Common Dividend
41.31%
16.03%
24.08%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
233,601
255,562
271,030
256,914
1,017,107
2025
240,550
251,518
280,010
245,348
1,017,427
2026
255,354
279,623
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
355
359
142
163.42
1,020
2025
4.16
106
404.92
249.65
766
2026
493.53
287
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
99.12
2025
- -
- -
- -
- -
100.02
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jeong-Gyun Kim
Full Time Employees
1,645
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Boryeong Building Seoul SL South Korea 03127
IPO Date
Oct 24, 1988
Website
boryung.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Boryung Corporation (003850.KS) engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. The company offers prescription drugs for hypertension including Kanarb (fimasartan), Kanarb Plus (ARB+HCTZ), Dukarb (ARB+CCB), and Tuvero (ARB+statin); dyslipidemia treatments; diabetes medications; central nervous system drugs; oncology drugs such as Gemzar, Genexol, and Xeloda; antibiotics including Maxipime; antiulcerants like Besto (H2RA) and Gelfos M (antacids); and active pharmaceutical ingredients (API). It operates across therapeutic categories encompassing cardiovascular, anti-infective, respiratory, and oncology segments, with exports to nearly 50 countries across six continents including Japan, China, Southeast Asia, the Middle East, Europe, South America, and Africa. Founded in 1957 and headquartered in Seoul, South Korea, at Boryung Building, 136 Changgyeonggung-ro, Jongno-gu, the company previously operated as Boryung Pharmaceutical Co., Ltd. until changing its name to Boryung Corporation in March 2022. Boryung Corporation maintains manufacturing facilities in Ansan and Yesan, employs approximately 1,533 people, and focuses on research and development for chronic disease treatments, incrementally modified drugs, and oncology pipelines. In recent developments, Boryung Corporation invested $10 million in shares of U.S.-based Intuitive Machines Inc. in December 2024 as part of its Humans in Space initiative, following a memorandum of understanding signed in October 2024 and prior investments in Axiom Space. The company received KRW 175 billion in funding from Boryung Partners Co. Ltd. in November 2024 and signed a global contract development and manufacturing organization (CDMO) agreement with Cheplapharm in 2025 to produce and supply Zyprexa tablets to 46 countries. Additionally, it expanded penicillin production facilities and advanced Korean generic anticancer drugs in 2025, while private equity firms Eugene PE and KDB PE agreed to acquire its subsidiary Boryung Biopharma for $231 million in June 2024.